Department of Radiation Oncology, Eberhard-Karls-University Tübingen, Hoppe-Seyler-Strasse 3, Tübingen, Germany.
Strahlenther Onkol. 2013 Jun;189(6):482-5. doi: 10.1007/s00066-013-0312-7. Epub 2013 Apr 21.
As treatment results for high-risk soft tissue sarcoma are still disappointing, treatment intensification is warranted. We performed a retrospective analysis of multimodal preoperative treatment to evaluate the additional effect of concurrent chemotherapy and/or locoregional hyperthermia in comparison to radiotherapy alone.
Between 1999 and 2011, 28 patients were treated with neoadjuvant radiotherapy to a median 45 Gy for high-risk soft tissue sarcoma. All tumors were deep-seated and grade 2 or 3, 86% (n = 24) larger than 5 cm. Multimodal treatment (n = 12) consisted of ifosfamide (n = 7), locoregional hyperthermia (n = 3), or both modalities (n = 2) concurrent to radiotherapy.
Prognostic factors (grade, size, histology, location) were balanced in the groups with and without concurrent multimodal treatment. There was a significant improvement of disease-specific survival (100% vs. 70% at 3 years, p = 0.03) with multimodal treatment. Distant metastases-free survival was influenced, but was not statistically significant. Local control and disease-free survival did not differ in the two groups.
Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas.
由于高危软组织肉瘤的治疗效果仍不尽如人意,因此需要加强治疗。我们对多模式术前治疗进行了回顾性分析,以评估与单独放疗相比,同期化疗和/或局部热疗的附加效果。
1999 年至 2011 年间,28 例高危软组织肉瘤患者接受新辅助放疗,中位剂量为 45Gy。所有肿瘤均位于深部,组织学分级为 2 级或 3 级,86%(n=24)的肿瘤直径大于 5cm。多模式治疗(n=12)包括异环磷酰胺(n=7)、局部热疗(n=3)或两者联合(n=2)同期放疗。
两组患者的预后因素(分级、大小、组织学、位置)均衡。与单独多模式治疗相比,联合治疗可显著提高疾病特异性生存率(3 年时为 100% vs. 70%,p=0.03)。远处无复发生存率受到影响,但无统计学意义。两组患者的局部控制率和无病生存率无差异。
我们的数据表明,异环磷酰胺和/或局部热疗联合新辅助放疗的多模式治疗可能改善高危软组织肉瘤的预后。